The Effects of AZT and Ibuprofen on HIV-Infected Patients With Hemophilia

• Register: ClinicalTrials.gov
• Last refreshed on: 17 October 2012
• Main ID: NCT00002276
• Date of registration: 02/11/1999
• Primary sponsor: University of Pittsburgh
• Public title: The Effects of AZT and Ibuprofen on HIV-Infected Patients With Hemophilia
• Scientific title: Study of Bleeding Tendency, Platelet Function, and Pharmacokinetics of Azidothymidine (AZT) and Motrin (Ibuprofen) in HIV-Infected Hemophiliacs
• Date of first enrolment: October 1997
• Recruitment status: Completed
• URL: http://clinicaltrials.gov/show/NCT00002276
• Study type: Interventional
• Study design: Primary Purpose: Treatment

Countries of recruitment

United States

Key inclusion & exclusion criteria

Inclusion Criteria

Patients must have:

- Hemophilia.

- HIV-seropositivity confirmed by Western Blot.

Prior Medication:

Required:

- AZT for study patients.

Allowed:

- Ibuprofen.

Exclusion Criteria

Co-existing Condition:

Patients with the following symptoms and conditions are excluded:

Hospitalization for opportunistic infection, bacterial infection or malignancy.

Concurrent Medication:

Excluded:

- AZT (for control group).

- Antibiotics or other medication for opportunistic infection, bacterial infection, or
malignancy.

Patients with the following prior conditions are excluded:

Hospitalization for opportunistic infection, bacterial infection, or malignancy.

Required:

- Ibuprofen.

- AZT 1-2 gm daily (for study patient) or not taking AZT (for control).



Age minimum: 12 Years
Age maximum: N/A
Gender: Both

Health Condition(s) or Problem(s) studied

Hemophilia A

HIV Infections

Intervention(s)

Drug: Ibuprofen

Drug: Zidovudine

Secondary ID(s)

044A

Source(s) of Monetary Support

Please refer to primary and secondary sponsors